These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 38305134)
1. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer. Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134 [TBL] [Abstract][Full Text] [Related]
2. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. Di Lisi D; Madaudo C; Alagna G; Santoro M; Rossetto L; Siragusa S; Novo G ESC Heart Fail; 2022 Jun; 9(3):1914-1919. PubMed ID: 35355425 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights. Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112 [TBL] [Abstract][Full Text] [Related]
4. Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice. Tini G; Cuomo A; Battistoni A; Sarocchi M; Mercurio V; Ameri P; Volpe M; Porto I; Tocchetti CG; Spallarossa P Int J Cardiol; 2022 Feb; 349():134-137. PubMed ID: 34848212 [TBL] [Abstract][Full Text] [Related]
5. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Rivero-Santana B; Saldaña-García J; Caro-Codón J; Zamora P; Moliner P; Martínez Monzonis A; Zatarain E; Álvarez-Ortega C; Gómez-Prieto P; Pernas S; Rodriguez I; Buño Soto A; Cadenas R; Palacios Ozores P; Pérez Ramírez S; Merino Salvador M; Valbuena S; Fernández Gasso L; Juárez V; Severo A; Terol B; de Soto Álvarez T; Rodríguez O; Brion M; González-Costello J; Canales Albendea M; González-Juanatey JR; Moreno R; López-Sendón J; López-Fernández T Eur Heart J; 2024 Aug; ():. PubMed ID: 39106857 [TBL] [Abstract][Full Text] [Related]
6. Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain. Nhat GM; Hai NH; Duc VT; Tri HHQ; Hoa CN Front Cardiovasc Med; 2024; 11():1291180. PubMed ID: 38312233 [TBL] [Abstract][Full Text] [Related]
7. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Battisti NML; Andres MS; Lee KA; Ramalingam S; Nash T; Mappouridou S; Senthivel N; Asavisanu K; Obeid M; Tripodaki ES; Angelis V; Fleming E; Goode EF; John S; Rosen SD; Allen M; Stanway S; Lyon AR; Ring A Breast Cancer Res Treat; 2021 Jul; 188(1):149-163. PubMed ID: 33818652 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer. Suntheralingam S; Fan CS; Calvillo-Argüelles O; Abdel-Qadir H; Amir E; Thavendiranathan P J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160296 [TBL] [Abstract][Full Text] [Related]
9. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline. Chang WT; Liu CF; Feng YH; Liao CT; Wang JJ; Chen ZC; Lee HC; Shih JY Arch Toxicol; 2022 Oct; 96(10):2731-2737. PubMed ID: 35876889 [TBL] [Abstract][Full Text] [Related]
10. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442 [TBL] [Abstract][Full Text] [Related]
11. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry. Shamai S; Rozenbaum Z; Merimsky O; Derakhshesh M; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Laufer-Perl M BMC Cancer; 2020 Jun; 20(1):609. PubMed ID: 32605637 [TBL] [Abstract][Full Text] [Related]
12. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034 [TBL] [Abstract][Full Text] [Related]
13. Cancer Therapeutics-Related Cardiac Dysfunction among Patients with Active Breast Cancer: A Cardio-Oncology Registry. Laufer-Perl M; Mor L; Milwidsky A; Derakhshesh M; Amrami N; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Rozenbaum Z Isr Med Assoc J; 2020 Sep; 22(9):564-568. PubMed ID: 33236555 [TBL] [Abstract][Full Text] [Related]
14. Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer. Cronin M; Crowley A; Davey MG; Ryan P; Abdelshafy M; Elkoumy A; Elzomor H; Arsang-Jang S; Ganly S; Nash P; Crowley J; Sharif F; Simpkin A; Lowery A; Wijns W; Kerin M; Soliman O J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835818 [TBL] [Abstract][Full Text] [Related]
15. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer. Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614 [TBL] [Abstract][Full Text] [Related]
16. Assessment of cancer therapy-related cardiac dysfunction in breast cancer women using a new speckle tracking echocardiography index: The GAVS. Di Lisi D; Madaudo C; Ortello A; Rubino L; Scelfo D; Sinagra FP; Comparato F; Triolo OF; Rossetto L; Galassi AR; Novo G Echocardiography; 2024 Aug; 41(8):e15881. PubMed ID: 39007868 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer. Thavendiranathan P; Shalmon T; Fan CS; Houbois C; Amir E; Thevakumaran Y; Somerset E; Malowany JM; Urzua-Fresno C; Yip P; McIntosh C; Sussman MS; Brezden-Masley C; Yan AT; Koch CA; Spiller N; Abdel-Qadir H; Power C; Hanneman K; Wintersperger BJ JAMA Cardiol; 2023 Jun; 8(6):524-534. PubMed ID: 37043251 [TBL] [Abstract][Full Text] [Related]
18. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial. Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243 [No Abstract] [Full Text] [Related]
19. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability. Altaha MA; Nolan M; Marwick TH; Somerset E; Houbois C; Amir E; Yip P; Connelly KA; Michalowska M; Sussman MS; Wintersperger BJ; Thavendiranathan P JACC Cardiovasc Imaging; 2020 Apr; 13(4):951-962. PubMed ID: 31864977 [TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]